N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

Simple item page
dc.contributor.authorORIGIN Trial
dc.contributor.authorBosch, Jackie
dc.contributor.authorGerstein, Hertzel C.
dc.contributor.authorDagenais, Gilles R.
dc.contributor.authorLejnieks, A.
dc.contributor.authorMarkova, I.
dc.date.accessioned2023-11-22T11:50:01Z
dc.date.available2023-11-22T11:50:01Z
dc.date.issued2012-07-26
dc.descriptionPublisher Copyright: Copyright © 2012 Massachusetts Medical Society.
dc.description.abstractBackground: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. Methods: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P = 0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P = 0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P = 0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P = 0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. Conclusions: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).en
dc.description.statusPeer reviewed
dc.format.extent10
dc.format.extent650619
dc.identifier.citationORIGIN Trial, Bosch, J, Gerstein, H C, Dagenais, G R, Lejnieks, A & Markova, I 2012, 'N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia', New England Journal of Medicine, vol. 367, no. 4, pp. 309-318. https://doi.org/10.1056/NEJMoa1203859
dc.identifier.doi10.1056/NEJMoa1203859
dc.identifier.issn0028-4793
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/14970
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=84864219466&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofNew England Journal of Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral Medicine
dc.subjectSDG 3 - Good Health and Well-being
dc.titleN-3 fatty acids and cardiovascular outcomes in patients with dysglycemiaen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
n_3_Fatty_Acids_and_Cardiovascular_Outcomes_in_Patients_with_Dysglycemia.pdf
Size:
635.37 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure